Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03396497
Recruitment Status : Recruiting
First Posted : January 11, 2018
Last Update Posted : September 5, 2018
Sponsor:
Information provided by (Responsible Party):
Lycera Corp.

Brief Summary:
This is a Phase 1B study designed to assess the safety and tolerability of LYC-55716 given in combination with pembrolizumab to subjects with metastatic NSCLC, and to assess the combination for biologic and clinical activity in NSCLC.

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Drug: LYC-55716 Drug: Pembrolizumab Phase 1

Detailed Description:

Approximately 18 subjects across 5 US sites will be enrolled in the study.

Subjects will enter a screening period of up to 28 days, followed by continuous twice daily administration of LYC-55716 in 28 day treatment cycles. Subjects will also be administered pembrolizumab every 3 weeks as prescribed as standard of care by the Investigator in accordance with the package insert.

The study will begin with a run-in cohort of 3 subjects to assess the safety and tolerability of the LYC-55716/pembrolizumab combination. Subjects in the run-in cohort will be enrolled singly at intervals of not less than 7 days in order to monitor for adverse reactions to the combination. If no subjects in the run-in cohorts has a DLT, then the study may proceed to the main cohort (15 subjects).

Subjects will receive combination treatment until clinically significant disease progression or unacceptable toxicity, or up to a maximum of 24 months.

Primary Study Objectives:

Run-in Cohort

  • Evaluate the safety and tolerability of the LYC-55716/pembrolizumab combination
  • Determine the dose of LYC-55716 that is adequately tolerated when used in combination with pembrolizumab

Main Study Cohort

• Further evaluate the safety and tolerability of the LYC-55716/pembrolizumab combination

Secondary Study Objectives:

Main Study Cohort

  • Evaluate the cellular immune response in paired tumor biopsy samples
  • Evaluate effects on circulating biomarkers in the blood of LYC-55716 with pembrolizumab
  • Determine the objective response rate
  • Determine the duration of response
  • Determine the progression-free survival (PFS) and overall survival (OS)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label Study of LYC-55716 in Combination With Pembrolizumab in Adult Subjects With Metastatic Non-Small Cell Lung Cancer
Actual Study Start Date : August 3, 2018
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : March 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: LYC-55716 + pembrolizumab
Subjects will receive combination treatment until disease progression or unacceptable toxicity, or up to a maximum of 24 months.
Drug: LYC-55716
Continuous twice daily administration of LYC-55716 in 28 day treatment cycles.

Drug: Pembrolizumab
Pembrolizumab administered every 3 weeks as prescribed as standard of care by the investigator in accordance with the package insert.




Primary Outcome Measures :
  1. Safety and tolerability will be assessed by the number of subjects with any treatment-emergent Adverse Events [ Time Frame: 12 weeks ]
    Common terminology criteria for adverse events (CTCAE) will be used for AE assessment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has histologic or cytologic confirmation of metastatic NSCLC. Subjects must have a TPS score available as determined by an FDA approved test. Subject has stable disease or disease progression and is being treated with pembrolizumab therapy as standard of care by the Investigator.
  • Subject is male or female and at least 18 years of age.
  • Subject has at least 1 measurable lesion per RECIST v1.1 criteria by computed tomography (CT) scan or magnetic resonance image (MRI).
  • Subject provides consent for fresh paired tumor biopsy samples to be obtained at screening and after 4 weeks of treatment (not required for run-in cohort or expansion of run-in cohort).
  • Subject has a life expectancy of at least 12 weeks
  • Subject has adequate organ function as determined by the following laboratory values:

    • ANC* ≥ 1500/mm³ (≥ 1.5 x 10^9/L)
    • Platelets* ≥ 100,000/mm³ (≥ 100 x 10^9/L)
    • Lymphocytes* ≥ 500/mm³ (≥ 0.5 x 10^9/L)
    • Hemoglobin* ≥ 9.0 g/dL
    • Serum Creatinine or Creatinine Clearance** ≤ 1.5 x ULN, > 50 mL/min
    • Total Serum Bilirubin ≤ 1.5 x ULN (< 3.0 mg/dL if subject has Gilbert's syndrome)
    • Liver Transaminases (ALT/AST) ≤ 2.5 x ULN, ≤ 5.0 x ULN if liver metastases present

      • (* = without ongoing growth factor or transfusion support)
      • (** = calculated by Cockcroft and Gault's formula)
      • (ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit of normal)

Exclusion Criteria:

  • Subjects may not have genomic aberrations such as ALK, EGFR, or BRAF for which there are FDA-approved targeted therapies available. Subjects may not have ROS1 aberration in accordance with the pembrolizumab label.
  • Subject has received an investigational drug in the 28 day period before the first dose of study drug (or within 5 half-lives if longer) or is currently participating in another interventional clinical trial.
  • Subject has known symptomatic brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Subjects with stable asymptomatic brain metastases or leptomeningeal disease are eligible provided that they have not required new treatments for this disease in a 28 day period before the first dose of study drug, and anticonvulsants and steroids have not been administered for a period of 2 weeks prior to the first dose of study drug.
  • Subject has not recovered from adverse reactions to prior cancer treatment or procedures (surgery, chemotherapy, immunotherapy, radiation therapy) to CTCAE Grade 2 or better.
  • Subject has a previous (within 5 years) or current malignancy other than the target cancer with the exception of curatively treated local tumors such as carcinoma in situ of the breast or cervix, basal or squamous cell carcinoma of the skin, or prostate cancer with Gleason Grade < 6 and prostate-specific antigen within normal range.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03396497


Contacts
Layout table for location contacts
Contact: H. Jeffrey Wilkins, MD 484-243-6222 wilkins@lycera.com

Locations
Layout table for location information
United States, Colorado
Lycera Investigational Site Recruiting
Aurora, Colorado, United States, 80045
United States, Michigan
Lycera Investigational Site Recruiting
Ann Arbor, Michigan, United States, 48109
United States, Tennessee
Lycera Investigational Site Recruiting
Nashville, Tennessee, United States, 37203
United States, Washington
Lycera Investigational Site Recruiting
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Lycera Corp.

Layout table for additonal information
Responsible Party: Lycera Corp.
ClinicalTrials.gov Identifier: NCT03396497     History of Changes
Other Study ID Numbers: LYC-55716-1002
First Posted: January 11, 2018    Key Record Dates
Last Update Posted: September 5, 2018
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents